全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

49例死亡乳腺癌患者的临床病理分析

, PP. 422-424

Keywords: 乳腺癌,临床病理,预后

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的探讨乳腺癌患者的临床病理学特点与预后的关系。方法回顾分析49例死亡乳腺癌患者(死亡组)的临床病理资料并与同期预后较好的女性乳腺癌患者49例(对照组)进行比较。结果死亡组淋巴结转移阳性率、临床分期Ⅲ期及C-erbB-2表达均高于对照组(P0.05)。结论乳腺癌患者的淋巴结转移、临床分期较晚及C-erbB-2过表达是预后不良的独立因素。

References

[1]  Rossi V,Sarotto I,Maggiorotto F,et al.Moderate Immunohistochemical Expression of HER-2(2+)Without HER-2 Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer[J].Oncologist,2012,17(11):1418-1425.
[2]  Ramadan SS,Yapicier O,Kihtir S,et al.Correlation of HER-2/neu gene amplification with immunohistochemistry and other prognostic factors in breast cancer noma[J].Turk Patoloji Derg,2011,27(3):196-203.
[3]  Zurita M,Lara PC,del Moral R,et al.Hypermethylated14-3-3-σ and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis[J].BMC Cancer,2010,10: 217-226.
[4]  Heneghan HM,Miller N,Lowery AJ,et al.Micro RNAs as novel biomarkers for breast cancer[J].J Oncol,2009,2009:950201.
[5]  龚建舟,张萍,俞晓立,等.影响乳腺癌术后精确放疗的因素分析[J].中国癌症杂志,2009,19(6):439-442.
[6]  中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2007版)[J].中国癌症杂志,2007,1(75):410-428.
[7]  Edge SB,Byrd DR,Compton CC,et al.AJCC Cancer Staging Manual[M].7th ed.New York:Springer,2010:347-376.
[8]  侯红波,田力平.乳腺癌210例预后影响因素分析[J].苏州大学学报:医学版,2006,26(1):154-156.
[9]  魏丽珍,林梅,何宏涛.1767例乳腺癌临床特点及发病因素分析[J].河北医科大学学报,2009,30(2):155-157.
[10]  Shaheenah Dawood,Kristine Broglio,Shu wan Kau,et al.Prognostic value of initial clinical disease stage after achieving pathological complete response[J].The Oncologist,2008,13:6-15.
[11]  沈伟娟,凌立君.乳腺癌患者综合治疗的疗效及预后分析[J].中国医药报导,2011,8(18):69-71.
[12]  张天泽,徐光炜.肿瘤学:中册[M].天津:天津科学技术出版社,1998:1410.
[13]  罗湘,史艳侠,李志铭,等.三阴乳腺癌的临床病理特征和预后分析[J].中国癌症杂志,2009,97(1):517-518.
[14]  周红兵,张秀忠.246例乳腺癌临床病理因素的预后分析[J].齐齐哈尔医学院学报,2011,30(24):3958-3960.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133